Delhi-based Morepen Labs has tied-up with Belgium’s Vesale Pharma to aggressively tap the growing probiotics market in India. The move is expected to contribute ₹100 crore to the Indian company’s topline in five years.

“We will soon be launching four major probiotics developed by Vesale Pharma in the Indian market. We hope to add ₹100 crore to the company’s top line in five years,” Sushil Suri, Chairman and Managing Director, Morepen Labs, told BusinessLine .

Probiotics has a market of about ₹1,000 crore in the country and it is growing at 15 per cent annually. “While the opportunity in the Indian market is huge, in our second phase of expansion we may look at exploring neighbouring markets such as Sri Lanka,” Suri said.

Explaining the unique feature of Vesale’s four products to be introduced in India, Pierre Iweins, Chairman of the company, explained that normally 90 per cent of the probiotics consumed by people gets destroyed in the stomach because of the gases present there and is of not much use to the body. “The products made by Vesal use a patented technology called ‘Intelicaps’ which does not let the probiotics get destroyed in the stomach and makes the live bacteria reach the intestine where it colonises and fights the bad bacteria,” Iweins said.

The four items include two for infants to treat diarrhoea and colic pain and two for adults to treat diarrhoea, maintain healthy digestive system and prevent constipation.

The agreement between Morepen Labs and Vesale Pharma was signed in the presence of the King and the Queen of Belgium who are on their State visit to India.

The items will be available in the market in the next two-three months, Suri said.

Initially, the two companies have got together for an exclusive distribution and marketing tie-up. However, Vesale may invest in future for setting up a worldwide manufacturing and R&D facility in India with Morepen for its entire range of products.

The global market for probiotics is worth $40 billion and is expected to double in the next 10 years, Iweins said.

comment COMMENT NOW